Mercado de biodefensa: mapeo competitivo y perspectivas estratégicas 2031

  • Report Code : TIPRE00005377
  • Category : Biotechnology
  • Status : Published
  • No. of Pages : 136
Buy Now

Se espera que el mercado de biodefensa alcance los 8.350,74 millones de dólares estadounidenses en 2027 desde los 4.108,24 millones de dólares estadounidenses en 2019. Se estima que el mercado crecerá con una tasa compuesta anual del 9,4% entre 2020 y 2027.< /h3>

La biodefensa se refiere a las medidas tomadas para restablecer la bioseguridad de un grupo de organismos que están, o pueden estar, sujetos a amenazas biológicas o enfermedades infecciosas. Es un sistema de atención de salud pública eficaz con una sólida vigilancia de las enfermedades y acciones rápidas diseñadas para contrarrestar las amenazas biológicas, limitar la propagación de enfermedades y brindar atención médica urgente. El crecimiento del mercado se atribuye a algunos factores impulsores clave, como la presencia de iniciativas gubernamentales favorables, el aumento del número de brotes naturales, la creciente amenaza de armas biológicas y misiles balísticos intercontinentales con armas nucleares. Sin embargo, se espera que la baja financiación de I+D por parte de los gobiernos en las economías en desarrollo y subdesarrolladas limite el crecimiento del mercado de biodefensa durante los años previstos.

Lucrativos mercados regionales de biodefensa



Perspectivas del mercado

Presencia de iniciativas gubernamentales favorables

< p>Cada año, el gobierno gasta mucho en I+D de vacunas para estar preparado ante cualquier ataque bioterrorista. Por ejemplo, en 2018, el gobierno de Estados Unidos publicó la Estrategia Nacional de Biodefensa y el Plan de Implementación, la Estrategia de Seguridad Nacional, la Estrategia de Defensa Nacional, la Estrategia Nacional de Contraterrorismo y la Estrategia Nacional de Lucha contra las ADM, todas las cuales incluyen bioseguridad y biodefensa. Además, el gobierno de EE. UU. también se está preparando para la Estrategia de Seguridad Sanitaria Global y apoyando el desarrollo de un marco para 2024 de la Agenda de Seguridad Sanitaria Global, que implica prevención, detección y respuesta a amenazas biológicas naturales, accidentales e intencionales.

Mejora las vacunas contra la influenza y la seguridad de la salud es el presupuesto que respalda la Orden Ejecutiva 13887, "Modernización de las vacunas contra la influenza en los Estados Unidos para promover la seguridad nacional y la salud pública", afirmó. proporcionando un aumento de $95 millones, en comparación con el nivel promulgado en 2020, en todos los Servicios Humanos y de Salud (HHS) para la infraestructura e innovación de fabricación de vacunas contra la influenza; investigación y desarrollo avanzados de vacunas, terapias y diagnósticos mejorados; preparación internacional para una pandemia; y una mejor cobertura de vacunación en todo el país. El Presupuesto también financia la adquisición de biodefensa y preparación para emergencias del HHS a través del programa BioShield y la Reserva Nacional Estratégica. Incluye $175 millones para apoyar las actividades de seguridad sanitaria global de los CDC, un aumento de $50 millones en comparación con el nivel promulgado en 2020.

A medida que el gobierno se involucra en estas actividades actuales y futuras actividades políticas, entendiendo la política existente de bioseguridad y biodefensa, las compañías farmacéuticas que operan en el mercado de biodefensa tienen oportunidades considerables para expandirse y estar preparadas para cualquier bioterrorismo. Por ejemplo, el desarrollador de antibióticos Spero Therapeutics ha recibido 15,7 millones de dólares en financiación federal para investigación de la Autoridad de Investigación y Desarrollo Biomédico Avanzado para su candidato de clase de carbapenem oral, SPR994, para evaluar la eficacia del fármaco contra amenazas biológicas, como el ántrax, la peste y la melioidosis. Además, la Autoridad de Investigación y Desarrollo Biomédico Avanzado también incluye provisiones por hasta $28,5 millones adicionales durante cinco años, y también apoyará el desarrollo clínico de Spero de SPR994 en infecciones complicadas del tracto urinario causadas por bacterias resistentes a los medicamentos. Las iniciativas de los gobiernos de todo el mundo abren una ventana de oportunidades para las empresas involucradas en el sector de la biodefensa.

Perspectivas del producto

El mercado de la biodefensa, por producto , se segmenta en ántrax, viruela, botulismo, radiación/nuclear y otros. En 2019, el segmento de ántrax representó la mayor cuota de mercado en el mercado mundial de biodefensa. Se espera que el segmento continúe su dominio durante el período previsto debido al aumento de la financiación por parte de los gobiernos de otros países para desarrollar y almacenar vacunas adecuadas contra el ántrax, principalmente a través de una variedad de iniciativas, como la Ley BioShield, la Autoridad de Investigación y Desarrollo Biomédico Avanzado (BARDA ), y la Oficina Ejecutiva del Programa Conjunto de Química y Tecnología. Defensa biológica.

Mercado global de biodefensa, por producto: 2018 y 2027



Información estratégica

La estrategia de lanzamientos de productos y aprobaciones es comúnmente adoptada por las empresas para expandir su presencia en todo el mundo y satisfacer la creciente demanda. Esta estrategia es adoptada más comúnmente por los actores del mercado para expandir su cartera de productos.

Los actores del mercado que operan en el mercado de biodefensa adoptan la estrategia de expansión para ampliar la base de clientes en todo el mundo, lo que también permite a los jugadores mantener su marca a nivel mundial. Por ejemplo, en enero de 2017, Emergent BioSolutions Inc. recibió la aprobación del Ministerio Federal de Salud de Alemania para comercializar BioThrax (vacuna contra el ántrax adsorbida) fabricada en el Edificio 55 en Alemania.

Mercado Mundial de Biodefensa - Por producto

  • Ántrax
  • Viruela
  • Botulismo
  • Radiación/Nuclear
  • Otros

Mercado de Biodefensa – ndash; Por geografía

  • América del Norte
    • Estados Unidos
    • Canadá
    • México
  • < li>Europa
    • Francia
    • Alemania
    • Italia
    • Reino Unido
    • España
    • Resto de Europa
  • Asia Pacífico
    • China
    • India
    • Corea del Sur
    • Japón
    • Australia
    • Resto de Asia Pacífico
  • Medio Oriente y Asia África
    • Sudáfrica
    • Arabia Saudita
    • EAU
    • Resto de Oriente Medio y África
  • América del Sur
    • Brasil
    • Argentina
    • Resto de América del Sur

Perfiles de empresas

  • Bavarian Nordic
  • Alnylam Pharmaceuticals, Inc.
  • SIGA Technologies
  • < li>Emergent BioSolutions Inc.
  • Cleveland Bio Labs
  • Dynavax Technologies
  • Elusys Therapeutics, Inc.
  • Soligenix
  • < li>Altimmune
  • Terapéutica Pluristem
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What is biodefense?

Biodefense is referred to the measures taken to restore biosecurity of a group of organism that are, or may be, subject to biological threats or infectious diseases. It is an effective public health care system with strong disease surveillance and rapid actions designed to counter biological threats, to limit the spread of disease and provide surge medical care.

What are the driving factors for the bioresorbable medical materials market across the globe?

Driving factors such as presence of favorable government initiatives increase in the number of naturally occurring outbreaks, increasing threat of biological weapons and nuclear armed ICBM. Additionally, the future trend such as predictive analytics to reshape biodefense market is likely to increase the growth in the forecast period.

What is the regional analysis in terms of bioresorbable medical materials?

Global biodefense market is segmented by region into North America, Europe, Asia Pacific, Middle East & Africa and South & Central America. In North America, the U.S. is the largest market for biodefense. Biological threats occurring to humans, animals and environment are among the most serious issues faced by the US and its national community. As the biological threat continues to increase, the US is focused towards strengthening its capabilities and considering preparation for bio threats and bioterrorism as one of the critical aspects of national security. The federal government in the US coordinates programs, and sets up budgets so as to prevent, respond and take actions against biological disasters.

The List of Companies - Biodefense Market

  1. Bavarian Nordic
  2. Alnylam Pharmaceuticals, Inc.
  3. SIGA Technologies
  4. Emergent BioSolutions Inc.
  5. Cleveland Bio Labs
  6. Dynavax Technologies
  7. Elusys Therapeutics, Inc.
  8. Soligenix
  9. Altimmune
  10. Pluristem Therapeutics

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports